NASDAQ:SHPH Shuttle Pharmaceuticals (SHPH) Stock Price, News & Analysis $1.70 0.00 (0.00%) (As of 02:38 PM ET) Add Compare Share Share Today's Range$1.55▼$1.7550-Day Range N/A52-Week Range$1.28▼$5.76Volume134,065 shsAverage Volume201,506 shsMarket Capitalization$28.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Shuttle Pharmaceuticals alerts: Email Address Ad DTIWeird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?Click here to see the 10 best trades upcoming in 2024 for FREE About Shuttle Pharmaceuticals Stock (NASDAQ:SHPH)Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.Read More SHPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SHPH Stock News HeadlinesSeptember 16 at 9:00 AM | globenewswire.comShuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaSeptember 5, 2024 | marketwatch.comShuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug StudySeptember 16, 2024 | Darwin (Ad)Curious About AI's Next Big Winners? 🚀Wondering which AI stocks are set to soar in 2024? We’ve identified the top 3, and we're excited to share them with you! Unlock immediate access to our exclusive report and discover... the key players and strategic insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.September 5, 2024 | msn.comWhy Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile TodaySeptember 4, 2024 | globenewswire.comShuttle Pharma Provides Second Quarter 2024 Corporate UpdateAugust 28, 2024 | markets.businessinsider.comShuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 27, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)August 26, 2024 | globenewswire.comShuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)September 16, 2024 | Darwin (Ad)Curious About AI's Next Big Winners? 🚀Wondering which AI stocks are set to soar in 2024? We’ve identified the top 3, and we're excited to share them with you! Unlock immediate access to our exclusive report and discover... the key players and strategic insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.August 14, 2024 | globenewswire.comShuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaJuly 19, 2024 | globenewswire.comShuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONEJune 18, 2024 | globenewswire.comShuttle Pharma Appoints Timothy Lorber as Chief Financial OfficerMay 22, 2024 | globenewswire.comShuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 14, 2024 | finanznachrichten.deShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 14, 2024 | globenewswire.comShuttle Pharma Provides First Quarter 2024 Corporate UpdateMay 13, 2024 | investorplace.comSHPH Stock Earnings: Shuttle Pharmaceuticals Reported Results for Q1 2024April 23, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 3, 2024 | globenewswire.comShuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024See More Headlines Receive SHPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shuttle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SHPH CUSIPN/A CIK1757499 Webwww.shuttlepharma.com Phone240-403-4212FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-217.60% Return on Assets-137.76% Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.83Miscellaneous Outstanding Shares16,795,000Free Float10,144,000Market Cap$28.38 million OptionableNot Optionable Beta-0.95 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Anatoly Dritschilo M.D. (Age 80)Co-Founder, CEO & Chairman of the Board Comp: $399.18kMr. Peter Dale Dritschilo M.B.A. (Age 55)M.D., President & COO Comp: $314.01kDr. Milton Brown CSC (Age 59)M.D., Ph.D., Co-Founder & Director Mr. Michael P. Vander Hoek (Age 64)CFO and VP of Operations & Regulatory Comp: $302.53kDr. Tyvin A. Rich M.D. (Age 76)Chief Clinical Officer & Chief Medical Officer Comp: $263.23kDr. Mira Jung Ph.D. (Age 75)Co-Founder & Chief Scientific Officer for Biology Mr. Gene Jung Esq.General CounselMore ExecutivesKey CompetitorsFlora GrowthNASDAQ:FLGCTenax TherapeuticsNASDAQ:TENXGuardion Health SciencesNASDAQ:GHSIConduit PharmaceuticalsNASDAQ:CDTOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsidersBette JacobsSold 33,256 sharesTotal: $1,912.22 ($0.06/share)View All Insider Transactions SHPH Stock Analysis - Frequently Asked Questions How have SHPH shares performed this year? Shuttle Pharmaceuticals' stock was trading at $1.96 at the beginning of the year. Since then, SHPH shares have decreased by 13.8% and is now trading at $1.69. View the best growth stocks for 2024 here. When did Shuttle Pharmaceuticals' stock split? Shuttle Pharmaceuticals's stock split before market open on Saturday, January 1st 2000. The 8-1 split was announced on Saturday, January 1st 2000. The newly minted shares were issued to shareholders after the closing bell on Tuesday, August 13th 2024. An investor that had 100 shares of stock prior to the split would have 800 shares after the split. When did Shuttle Pharmaceuticals IPO? Shuttle Pharmaceuticals (SHPH) raised $10 million in an IPO on Wednesday, August 31st 2022. The company issued 1,225,888 shares at $8.13 per share. How do I buy shares of Shuttle Pharmaceuticals? Shares of SHPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SHPH) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shuttle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
